RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced an update on its clinical development activities and financial status. Namodenoson drug candidate: Can-Fite is currently enrolling patients in a pivotal Phase III clinical study evaluating Namodenoson for the treatment of advanced hepatocellular carcino ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placeboThe safety profile of tolebrutinib was consistent with previous studies Paris, December 15, 2025. Results from the PERSEUS phase 3 study (clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpo ...

From what we can see, so far, most major Wall Street strategists are currently forecasting that the S&P 500 will finish 2026 up quite a bit above current levels. Current targets cluster around the 7,400 to 8,100 range. JustI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciat ...

InMed Pharmaceuticals (NasdaqCM:INM) 2025 Conference December 11, 2025 02:00 PM ET Company ParticipantsEric Adams - CEO and PresidentModeratorConferences. On behalf of OTC Markets, we're very pleased you joined us for the Life Sciences Investor Forum. Our next presentation. Please note you may submit questions for the presenter in the box to the left of the slides. You can also view a company's availability for one-on-one meetings by clicking "Book a Meeting" in the top toolbar. At this point, I'm very plea ...

The scale of IQVIA Holdings ( IQV ) in healthcare information, real-world evidence collection, and AI-enabled trials and commercialization make it much more than a large CRO. Other CROs compete for share within the contract researchDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplin ...

Redwire Corporation ( RDW ) has had a pretty tough 2025, with shares down about 55% since the beginning of the year. And despite all the global conflicts and increased demand for unmanned drones, the stock has failed to maintain the levels of $20 weI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific found ...

BigBear.ai ( BBAI ) have just made a couple of interesting announcements over the past month. Both announcements point to having a nice foothold in the Middle East. The company first revealed a partnership with Vigilix andI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciati ...

公司财务表现 - 公司2025财年第三季度非美国通用会计准则每股收益为-0.22美元，超出市场预期约0.09美元[1] - 公司2025财年第三季度营收为3960万美元，略低于市场共识94万美元[1] 分析师背景 - 分析师拥有细胞生物学硕士学位，并曾作为实验室技术员在药物发现诊所工作多年，在细胞培养、检测开发和治疗研究方面拥有丰富的实践经验[1] - 分析师过去五年活跃于投资领域，其中最近四年在从事实验室工作的同时兼任生物技术股票分析师[1] - 分析师的研究重点是通过结合实验室科学专业知识与金融和市场分析，识别以独特和差异化方式创新的生物技术公司[1]

公司近期股价表现与催化剂 - Rezolute Inc (RZLT) 股票近期呈现明显的上升趋势 市场对其候选药物Ersodetug的潜力越来越乐观 [1] - 有几个积极的催化剂即将到来 [1] 分析师背景与研究方法 - 分析师拥有细胞生物学硕士学位 并曾作为实验室技术员在药物发现诊所工作多年 在细胞培养、检测开发和治疗研究方面拥有丰富的实践经验 [1] - 其科学背景使其深刻理解药物开发背后的严谨性和挑战 并将此融入其作为投资者和分析师的工作中 [1] - 过去五年活跃于投资领域 其中最近四年在从事实验室工作的同时 兼任生物技术股票分析师 [1] - 其研究重点是识别以独特和差异化方式进行创新的生物技术公司 无论是通过新颖的作用机制、首创疗法 还是有可能重塑治疗范式的平台技术 [1] - 通过将实验室的科学专业知识与金融和市场分析相结合 旨在提供技术上可靠且以投资为导向的研究 [1] - 在Seeking Alpha上 计划主要撰写生物技术领域的文章 涵盖从早期临床管线到商业阶段生物技术等不同发展阶段的公司 [1] - 分析方法强调评估候选药物背后的科学原理、竞争格局、临床试验设计和潜在市场机会 同时平衡财务基本面和估值 [1] - 其目标是分享见解 帮助投资者更好地理解生物技术领域的机遇 [1] - 该领域突破性科学可以转化为超额回报 但也需要进行仔细的审查 [1]

公司近期股价表现与催化剂 - Rezolute公司股票近期呈现显著上升趋势 市场对其候选药物Ersodetug的潜力越来越乐观 [1] - 有几个积极的催化剂即将到来 [1] 分析师背景与研究方法 - 分析师拥有细胞生物学硕士学位 并曾作为实验室技术员在药物发现诊所工作数年 在细胞培养、检测开发和治疗研究方面拥有丰富的实践经验 [1] - 其科学背景使其深刻理解药物开发背后的严谨性和挑战 并将此融入其作为投资者和分析师的工作中 [1] - 过去五年活跃于投资领域 其中最近四年在从事实验室工作的同时 兼任生物技术股票分析师 [1] - 其研究重点是识别以独特和差异化方式进行创新的生物技术公司 无论是通过新颖的作用机制、同类首创疗法 还是有可能重塑治疗模式的平台技术 [1] - 通过将基于实验室的科学专业知识与金融和市场分析相结合 旨在提供技术上可靠且以投资为导向的研究 [1] - 分析方法强调评估候选药物背后的科学原理、竞争格局、临床试验设计以及潜在的市场机会 同时平衡财务基本面和估值 [1]